Kura Oncology Inc. (KURA) Stock Rating Upgraded by Zacks Investment Research
Kura Oncology Inc. (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Separately, Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $16.00 target price on shares of Kura Oncology in a research report on Sunday, August 14th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Kura Oncology presently has an average rating of “Buy” and an average price target of $14.15.
Shares of Kura Oncology (NASDAQ:KURA) opened at 5.76 on Wednesday. Kura Oncology has a 12 month low of $2.50 and a 12 month high of $25.00. The stock has a 50 day moving average price of $6.15 and a 200 day moving average price of $4.19. The stock’s market capitalization is $107.96 million.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 10th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.02. On average, analysts anticipate that Kura Oncology will post ($1.58) EPS for the current fiscal year.
An institutional investor recently bought a new position in Kura Oncology stock. Minerva Advisors LLC purchased a new stake in Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 361,737 shares of the company’s stock, valued at approximately $977,000. Minerva Advisors LLC owned 1.96% of Kura Oncology at the end of the most recent quarter. Hedge funds and other institutional investors own 43.63% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.